Soon a new product SindranolÒ (INN ropinirol, prolonged release) for Parkinson disease will emerge. It delays progression of the disease and makes the life of patients with that diagnosis easier.
Studies have shown that ropinirol exerts positive effect delaying development of hypokinesia, muscle rigidity, tremor. This drug helps delay symptoms like dementia, sleeplessness, psychosis and other signs of the disease.
Further treatment with SindranolÒ in combination with levodopa enables to minimize the dose o the latter and reduce the rate of motor complications of treatment.
This drug is manufactured by EGIS, a pharmaceutical company that is constantly extending its portfolio of significant drugs in the neurology section.